Covid-19 roundup: Moderna enlists Catalent as manufacturing partner, securing fill-finish capacity for the first 100M doses
Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo
COVID-19 drug remdesivir recommended for EU approval
Coronavirus pharma news roundup – 26/06/20
One coronavirus vaccine stock is up 750% this year. Could the rest follow?
Gilead Aims To Produce More Than 2 Million Remdesivir Courses By Year-End
Gilead targets two million remdesivir courses by year-end
Cipla launches COVID-19 drug remdesivir in India as disease takes hold
UK team awarded grant for ‘second wave’ COVID-19 drug hunt
Mixed results for Roche drugs in prostate cancer and COVID-19
Boehringer Ingelheim nabs new US president and CEO; AstraZeneca vet hops aboard Novavax as CMO
Coronavirus pharma news roundup – 19/06/20
Gilead will test remdesivir in children with COVID-19
Off-the-shelf tool for making mouse models of COVID-19
FDA warns against combination of malaria drug and Gilead’s remdesivir
Is Now Still a Good Time to Buy Gilead Sciences (GILD) Stock? Oppenheimer Says 'Yes'
Eli Lilly launches PhIII JAK study, aiming for the first drug to lower mortality in Covid-19
Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir
Florida Reports Another Record Jump In New Cases As Global COVID-19 Count Nears 8 Million: Live Updates
Coronavirus pharma news roundup – 12/06/20
The unprecedented challenge of pricing a coronavirus vaccine
Gilead Merger Unlikely at This Point, Says 5-Star Analyst
What Would a Merger Mean for Gilead? Top Analyst Weighs In
AstraZeneca ‘probably couldn’t run Gilead any better:’ analyst
Watchdog Aims for Speedy Remdesivir Approval
"V"-Shaped Economic Projections Will Leave Everyone Disappointed
20/20 Economic Projections Will Leave Everyone Disappointed
AZ reportedly mulls biggest-ever pharma merger with Gilead
AstraZeneca Approached Gilead For Potential Merger - Report
What Are the Implications of Gilead’s Increased Focus on Oncology? 5-Star Analyst Weights In